<p>The company's proprietary insomnia agent, NG2-73, an alpha-3 preferring GABA partial agonist, achieved positive top-line results from two dose-ranging, phase 2b clinical trials.<br /><br />Multiple formulations were studied in each trial to determine the best profile for rapidity of sleep onset and maintenance of sleep through the night without residual sedation the next day.<br /><br />NG2-73 achieved statistically significant results versus placebo at all doses tested in the primary endpoint of sleep maintenance, sleep onset, and reducing wake after sleep onset at all dose and formulation profiles tested. <br /><br />Commenting on the results, William Koster, president and CEO of Neurogen, said, We wanted to answer two questions in these trials. First, can we achieve our target profile in chronic insomnia patients of rapid onset of sleep which is maintained throughout the night without next-day residual effects and, second, do we have a controlled release formulation of the drug that we believe we can take forward? The results of these studies indicate the answer to both questions is yes.</p>